

NCI Director's Report


Norman E. Sharpless, M.D.

*7th Virtual Meeting of the Frederick National
Laboratory Advisory Committee*

June 28, 2021

@NCIDirector
@TheNCI

Redesigned FNL website



Enhancing awareness of the Frederick National Laboratory



- **What is the Lab?**
 - **What does it offer?**
 - **How can researchers use it?**
-

AUDIENCES

- Extramural researchers
- Members of Congress
- Cancer research advocates
- Partners and potential partners


FFRDC Contract Recompetition Update

- Industry Day held on April 8th
 - Registrants – ~130 potential prime contractor individuals; ~110 potential subcontractor individuals
 - Over 25 Government presentations -- Recorded for future viewing
- **Draft Request for Proposal (RFP) issued on June 24th - Response date: July 23rd**
 - **Posted to: Beta Sam at <https://beta.sam.gov/>**
- RFP Issuance contemplated for 1st Quarter FY22. Receipt of Proposals contemplated for 3rd Quarter FY22.
- Contract Award is planned in Fall 2023, subject to change.
- The Government expects to provide 150 days for proposal response.
- Additional information concerning the competitive process will be announced on the Government-wide point of entry, Beta Sam at <https://beta.sam.gov/>, as well as at the FNLCR Acquisition Portal at <https://www.cancer.gov/about-nci/contracts/fnlcr-acquisitions>.
- Questions regarding this acquisition should be directed to the Contracting Officer via FNLCR_ACQinfo@nih.gov


NCI Appropriations

FY 2015 – 2022 (in millions)

21st Century Cures Act - orange
Childhood Cancer Initiative - green



The volume of R01 applications to NCI continues to outpace those across NIH



U.S.-U.K. Bilateral Cancer Summit



Doug Mills/The New York Times

“We will convene the first U.S.-U.K. Bilateral Cancer Summit and bring together researchers, patients, and other stakeholders to share ideas and identify opportunities for collaboration to accelerate advances in lifesaving approaches to cancer, which remains a leading cause of death worldwide.”

- Joint statement issued June 10, 2021

NCI COVID-19 in Cancer Patients Study (NCCAPS)

875

TRIAL SITES
ACTIVATED
IN

50

STATES
+ DC, PUERTO
RICO, AND
CANADA

Special emphasis on
minority,
underserved and
rural communities

Participants
will be
followed for
2 years

1,137
ENROLLED

88 pediatric patients
enrolled

Launched May 21, 2020
Conception to Launch in
6 weeks


Aims to enroll
2,000 patients
across 1,000
sites in U.S.

ASCO 21
ABSTRACTS


#6565
#6566

Impact of COVID-19 pandemic on cancer screening in the US

Breast Cancer Screening (Mammography)



Colorectal Cancer Screening (Colonoscopy and FIT)




Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective From the National Cancer Institute's PROSPR Consortium. Gastroenterology, Volume 160, Issue 4, 999 - 1002

NCI Equity and Inclusion Program


EQUITY COUNCIL	Chair Ned Sharpless Co-Chair Paulette Gray	Mark Alexander Andrea Apolo Nelvis Castro Bob Croyle	Montse Garcia-Closas Anne Lubenow Ji Luo	Donna Siegle Dinah Singer Sanya Springfield
WORKING GROUP 1 <i>Enhancing Research to Address Cancer Health Disparities</i> CO-CHAIRS Jim Doroshow Worta McCaskill-Stevens Tiffany Wallace	WORKING GROUP 2 <i>Ensuring Diversity of Thought and Background in the Cancer Research Workforce</i> CO-CHAIRS LeeAnn Bailey Susan McCarthy Glenn Merlino	WORKING GROUP 3 <i>Promoting an Inclusive and Equitable Community at NCI</i> CO-CHAIRS Shannon Bell Satish Gopal Paige Green	WORKING GROUP 4 <i>Systematic Tracking and Evaluation of Equity Activities</i> CO-CHAIRS Michelle Bennett Doug Lowy	WORKING GROUP 5 <i>Communications and Outreach for Equity Activities</i> CO-CHAIRS Peter Garrett Angela Jones Anita Linde

Demographics of NCI R01 Equivalent PIs (FY 2020)



*More than one race, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander

Demographics of NCI R01 Equivalent PIs (FY 2020)




*More than one race, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander

Data Source: Data from NIH OER with analysis by NCI Center for Research Strategy. **Method:** Percents rounded to nearest 1%. Percentages are calculated using the number of PIs that have self-reported their race or ethnicity (92% of all PIs). Hispanic may be any race; race categories exclude Hispanic origin.

Immediate Action: Early Investigator Advancement Program

Goal: To promote the transition of extramural and intramural early career investigators to independent investigators

Program Components



Outcomes for Each Participant

- Complete an R01 grant proposal
- Become part of a group of peers with similar career goals
- Engage with mentors who are established investigators
- Become familiar with job and funding opportunities
- Develop professional and management skills critical to growing a research group

- *20 participants per cohort*
- *1 cohort per year*

CUSP2CT Connecting Underrepresented Populations to Clinical Trials

PURPOSE

To implement and evaluate multi-level and culturally tailored outreach and education interventions with the primary goal to increase referral of racial/ethnic minority populations to NCI-supported clinical trials.



CUSP2CT Network – FY 22- 26

- Data, Evaluation, and Coordinating Center – 1 U24
- Up to 4 U01s



Will enhance clinical trial participation among racial/ethnic minority populations through a partnership of

- **Community Health Educators**
- **Lay Health Advisors**
- **Clinical Trial Coordinators**
- **Referring providers (primary care and oncologists)**

SEER Coverage As of June 2021



Cancer MoonshotSM



Human Tumor Atlas Network Data Portal

Welcome to the HTAN Data Portal!

The Human Tumor Atlas Network (HTAN) is a National Cancer Institute (NCI)-funded Cancer MoonshotSM initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease.

Explore the Data

9

Atlases

8

Organs


509

Cases

1260

Biospecimens

Over 50,000 oncology patients reached by an NCI Cancer Center Cessation Initiative (C3I) tobacco treatment program since 2018



Courtesy of Dr. Betsy Rolland, C3I PI. Data through April 15, 2021.




Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N.J. Tutt, M.B., Ch.B., Ph.D., Judy E. Garber, M.D., M.P.H., Bella Kaufman, M.D., Giuseppe Viale, M.D., Debora Fumagalli, M.D., Ph.D., Priya Rastogi, M.D., Richard D. Gelber, Ph.D., Evandro de Azambuja, M.D., Ph.D., Anitra Fielding, M.B., Ch.B., Judith Balmaña, M.D., Ph.D., Susan M. Domchek, M.D., Karen A. Gelmon, M.D., et al., for the OlympiA Clinical Trial Steering Committee and Investigators*

3-year invasive disease-free survival	Placebo 77.1%	3-year distant disease-free survival	Placebo 80.4%
	Olaparib 85.9%		Olaparib 87.5%
<i>Difference: 8.8 percentage points 95% CI: 4.5 to 13.0.</i>		<i>Difference: 7.1 percentage points 95% CI: 3.0 to 11.1</i>	

Proteogenomic and metabolomic characterization of human glioblastoma

- Phosphorylated PTPN11 and PLCG1 represent a signaling hub in RTK-altered tumors
- Four immune GBM subtypes exist, characterized by distinct immune cell populations
- Mesenchymal subtype EMT signature is specific to tumor cells, but not to stroma
- Histone H2B acetylation is enriched in classical GBMs with low macrophage content



National Cancer Act of 1971 50th Anniversary



Discussion